Cargando…

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population

OBJECTIVE: Plasma Epstein-Barr virus (EBV) DNA is considered a biomarker for nasopharyngeal carcinoma (NPC). However, its long-term role in NPC development is unclear. MATERIALS AND METHODS: A total of 1363 participants seropositive for EBV VCA-IgA and EBNA1-IgA in a community-based NPC screening pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wen-Jie, Xu, Wen-Na, Wang, Hai-Yun, Chen, Xiao-Xia, Li, Xue-Qi, Xie, Shang-Hang, Lin, Dong-Feng, Cao, Su-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168313/ https://www.ncbi.nlm.nih.gov/pubmed/34074258 http://dx.doi.org/10.1186/s12885-021-08408-0

Ejemplares similares

Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma
por: Li, Wangzhong, et al.
Publicado: (2023)

Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma
por: Chen, Meng, et al.
Publicado: (2015)

Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein‐Barr Virus: An analysis of a prospective study in southern China
por: Hu, Ting, et al.
Publicado: (2019)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study
por: Tang, L-Q, et al.
Publicado: (2014)

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
por: Zhu, Qian-Ying, et al.
Publicado: (2020)

Nasopharyngeal Epstein‐Barr virus DNA loads in high‐risk nasopharyngeal carcinoma families: Familial aggregation and host heritability
por: Zheng, Mei‐Qi, et al.
Publicado: (2020)

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma
por: Prayongrat, Anussara, et al.
Publicado: (2017)

Combining pretreatment plasma Epstein‐Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study
por: Du, Yu‐Yun, et al.
Publicado: (2019)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma
por: Liao, Ying, et al.
Publicado: (2023)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Identification of genes involved in Epstein-Barr virus-associated nasopharyngeal carcinoma
por: Wang, Junguo, et al.
Publicado: (2016)

Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population
por: Mao, Min-jie, et al.
Publicado: (2018)

Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study
por: Liang, Fa-Ya, et al.
Publicado: (2012)

Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein-Barr virus genetic variants
por: Cui, Qian, et al.
Publicado: (2016)

The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study
por: Liu, Sai-Lan, et al.
Publicado: (2019)

Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells
por: Tsang, Chi Man, et al.
Publicado: (2014)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort
por: Sun, Xue‐Song, et al.
Publicado: (2019)

Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus–Related Nasopharyngeal Carcinoma
por: Li, Wang-Zhong, et al.
Publicado: (2021)

Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy
por: Peng, Hao, et al.
Publicado: (2016)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Synergistic Association of Hepatitis B Surface Antigen and Plasma Epstein-Barr Virus DNA Load on Distant Metastasis in Patients With Nasopharyngeal Carcinoma
por: Li, Haojiang, et al.
Publicado: (2023)

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Variations of Epstein-Barr Virus Nuclear Antigen 1 in Epstein-Barr Virus-Associated Gastric Carcinomas from Guangzhou, Southern China
por: Chen, Jian-ning, et al.
Publicado: (2012)

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Prognostic Value of Oral Epstein–Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma
por: He, Yong-Qiao, et al.
Publicado: (2022)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Quantification of Epstein–Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China
por: Zheng, Xiao-Hui, et al.
Publicado: (2015)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

Integration Profiling Between Plasma Lipidomics, Epstein–Barr Virus and Clinical Phenomes in Nasopharyngeal Carcinoma Patients
por: Huang, Yi, et al.
Publicado: (2022)

Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein–Barr Virus Infection
por: Liu, Xue, et al.
Publicado: (2022)

Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma
por: Xu, Miao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dl1s1v6icilpekfcpt779igo9k